Frankly, it really is state-of-the-art. There's only a handful of these things in the United States. There's some bigger ones, maybe some more impressive ones, but that facility they have there is terrific, no question about it.

Biotech appeared to be a defensive play.

Biotech investing is no longer a pie-in-the-sky game.

Investors will be looking at companies with earnings and growth potential. They're not going to wait two years for drug discovery and four years for product development. And that leaves a lot of biotech companies off the radar.

They are at the starting line now. They have all the bioreactors in there. The pipes are connected. All the switches work. Now they have to get clearance.

Typically, they are faster to generate revenue and, hopefully, faster to profitability.

If the once-a-month data were equivalent, it would have been a home run. Efficacy is what primarily drives the hepatitis C market.